Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.
Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.
复制标题
DOI：
10.1016/j.clbc.2019.11.010
复制
发表时间：
2020-06
影响因子：
3.1
通讯作者：
Serrero G
中科院分区：
文献类型：
--
作者：
Tkaczuk KHR;Hawkins D;Yue B;Hicks D;Tait N;Serrero G
颗粒蛋白前体（GP 88）在乳腺肿瘤发生中起关键作用。与健康个体相比，GP 88肿瘤表达与复发和死亡率增加相关，而GP 88循环水平在乳腺癌患者中升高。我们在此研究了转移性乳腺癌（MBC）患者血清GP 88水平与总生存率和疾病状态（确定为对治疗的反应或疾病进展）之间的相关性。一项机构审查委员会（IRB）批准的研究在马里兰州大学Marlene和Stewart Greenebaum综合癌症中心（UMGCCC）前瞻性招募了101名MBC患者。GP 88血清水平与按RECIST 1.1标准确定的患者疾病状态和生存结局相关，Kaplan Meier分析和Logrank统计。根据血清GP 88水平对患者的生存率进行分层。血清GP 88 <55 ng/ml的患者的存活率比GP 88> 55 ng/ml的患者高4倍。对与疾病状态相关的GP 88血清水平的检查显示，血清GP 88水平、疾病进展或对治疗的反应之间存在统计学显著相关性。血清GP 88水平与生存率和疾病状态的相关性表明，血清GP 88检测可用于监测MBC患者的疾病状态。MBC患者血清GP 88水平的测量可能具有临床价值，可作为MBC患者影像学管理的成本效益指南。颗粒蛋白前体（GP 88）是乳腺肿瘤发生的驱动因素。高肿瘤表达与复发和死亡率增加相关。在101例转移性乳腺癌患者中检查了血清GP 88与生存率和疾病状态之间的相关性。血清GP 88水平与生存率、治疗反应和疾病进展相关。这些数据将建议血清GP 88测量以监测疾病的标准护理。status.in
Progranulin (GP88) is a critical player in breast tumorigenesis. GP88 tumor expression is associated with increased recurrence and mortality while GP88 circulating levels are elevated in breast cancer patients, compared to healthy individuals. We examined here the correlation between serum GP88 levels in metastatic breast cancer (MBC) patients with overall survival and disease status determined as response to therapy or progression of disease. An institutional review board (IRB) approved study prospectively enrolled 101 MBC patients at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). GP88 serum levels were correlated with patients’ disease status determined by RECIST 1.1 criteria and survival outcomes by Kaplan Meier analysis and Logrank statistics. Patients’ survival was stratified by serum GP88 level. Patients with serum GP88 <55 ng/ml had a four-fold increased survival compared to patients with GP88 > 55 ng/ml. Examination of GP88 serum levels in association with disease status showed a statistically significant association between serum GP88 levels disease progression or response to therapy. The association of serum GP88 level with survival and disease status suggests the potential of using serum GP88 test for monitoring disease status in MBC patients. Measurement of serum GP88 levels in MBC patients may have clinical value as a cost-effective adjunctive to imaging MBC patient management. Progranulin (GP88) is a breast tumorigenesis driver. High tumor expression is associated with increased recurrence and mortality. Correlation between serum GP88 with survival, and disease status was examined in 101 metastatic breast cancer patients. Serum GP88 levels correlated with survival, therapy response and disease progression. These data would suggest serum GP88 measurement to monitor disease status.in the standard of care.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.3
作者：
Greither, Thomas;Fischer, Kersten;Lieb, Verena
通讯作者：
Lieb, Verena
DOI：
10.1007/s12032-017-1054-7
发表时间：
2017-11-07
期刊：
Medical oncology (Northwood, London, England)
影响因子：
--
作者：
Arechavaleta-Velasco F;Perez-Juarez CE;Gerton GL;Diaz-Cueto L
通讯作者：
Diaz-Cueto L
DOI：
10.1158/1055-9965.epi-16-0889
发表时间：
2017-06
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Mariotto AB;Etzioni R;Hurlbert M;Penberthy L;Mayer M
通讯作者：
Mayer M
影响因子：
--
作者：
Accordino, Melissa K.;Wright, Jason D.;Hershman, Dawn L.
通讯作者：
Hershman, Dawn L.